Valencell announces world's first calibrationless blood pressure sensor

With cuffs and calibration kits, measuring your blood pressure can be a bit of a pain — literally for some. But Valencell’s latest product looks to eliminate the hassles that come with measuring blood pressure by putting all the technology into a single device.

Valencell — a company that has put its sensor technology in products from Sony, Samsung, Suunto, Bose, Jabra, and Huawei — has announced that it’s developing its own digital therapeutics portfolio. The first entry in its product line is a cuffless, calibration-free blood pressure monitor that it has brought to CES 2023.

“In reviewing our company strategy, we concluded developing our own solutions was the most effective way to get to market faster since the lion’s share of the regulatory and research development already falls upon Valencell,” said Dr. Steven LeBoeuf, President and co-founder of Valencell. “Beginning with the number one silent killer, hypertension, Valencell is developing digital health solutions that take out all the friction and barriers to capturing and acting on health data to help make it easier for people to take control over their health, live longer, healthier, and more productive lives.”

Valencell’s monitor uses Photoplethysmography (PPG) sensors to measure blood flow patterns. Combined with the company’s AI algorithms and PPG datasets from over 7,000 patients, the device is said to be able to process your information with physical characteristics and calculate accurate diastolic and systolic results that are displayed on the gadget’s built-in screen.

In addition, the company is developing a mobile app that your diastolic and systolic results would be sent to. Along with storing your results, the app would reportedly also create a blood pressure profile for you, as well as help users improve their cardiovascular health through targeted diet and exercise plans. The company also says that it plans to expand app integration within digital healthcare platforms used by healthcare providers to improve physician-directed care.

Aimed at being an over-the-counter solution to help those with hypertension, the device would be the world’s first standalone blood pressure monitor. Before that can happen, however, it first needs to earn FDA clearance, which Valencell believes will happen in late 2023. If the device makes it to market, Valencell plans on selling it for $99.